Clinic facilities

NAMSA to Acquire Europe-Based Medanex Clinic to Expand Early-Stage Preclinical Research Capabilities | News

TOLEDO, Ohio & DIEST, Belgium–(BUSINESS WIRE)–March 30, 2022–

NAMSAa world-leading MedTech contract research organization (CRO) providing end-to-end global development services, today announced its pending acquisition of Medanex Clinica European preclinical research organization based in Belgium.

Founded in 2010, Medanex focuses on providing exceptional preclinical services to the medical device industry in Europe and worldwide. Their team of internationally acclaimed cardiovascular surgeons and staff are well known for guiding clients through the preclinical study design pathway to achieve successful results. World-renowned companies, as well as small, innovative research groups, regularly partner with Medanex for their exceptional cardiovascular services and fast, effective study results.

“NAMSA is very excited to expand its European preclinical services with the addition of Medanex,” said Dr. Christophe Berthoux, CEO of NAMSA. “Their strong preclinical capabilities and expertise, particularly in the cardiovascular field, will help improve the NAMSA customer experience. We are delighted to partner with an organization that strongly shares our core values ​​and our desire to accelerate the development of medical devices worldwide,” concluded Dr. Berthoux.

As the global leader in the medical device testing industry, NAMSA has amassed the greatest breadth and depth of therapeutic expertise and knowledge than any other preclinical development partner in the industry. The organization’s preclinical research services provide support for all types of implant designs, treatments and requirements. NAMSA also offers Customers the benefit of full continuum development services, including regulatory, reimbursement, quality and clinical research services reduce delays up to 30 percent above industry averages.

“Medanex is proud to be part of the NAMSA family. With a similar vision to provide world-class expertise and exceptional service and resources to the medical device industry, we are ideally aligned. For 12 years, we have become a trusted and respected partner for the most challenging surgical studies while remaining customer-focused and striving for scientific excellence,” said Medanex CEO, Hadewych Van Hauwermeiren. “With NAMSA’s complementary expertise and resources, we will serve our customers in an even greater capacity and we look forward to joining the world’s leading CRO for cardiovascular research,” concluded Van Hauwermeiren.

The acquisition of Medanex Clinic increases NAMSA’s scale in Europe and its growing global presence, now serving clients in 20 locations across the Americas, Asia-Pacific and Europe.

The price and terms of the upcoming transaction are not disclosed.

ABOUT NAMSA

Helping medical device developers improve healthcare since 1967, NAMSA is the world’s premier MedTech contract research organization (CRO) offering end-to-end global development services. Driven by its global regulatory expertise and deep therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move customers’ products through the development lifecycle of efficient and profitable way. Medical device testing; regulatory, reimbursement and quality advice; and clinical research services, NAMSA is the industry’s premier trusted partner for successful development and commercialization results. The Web: www.namsa.com

ABOUT Medanex

Medanex Clinic is a CRO passionate about excellence. As such, it is committed to “raising the bar” in all aspects of preclinical research, from impeccable in vivo studies to highly regarded customer service and exceptional animal welfare. Medanex masters a wide range of preclinical surgical models in different disciplines. Experienced veterinarians assist or perform a wide variety of procedures. A large network of experts in human medicine is available for consultation to perform specialized surgeries. The Web: http://medanex.com/

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220330005109/en/

CONTACT: NAMSA Media Contact

Leah Davidson, MA, MBA, PCM

Senior Manager, Global Marketing Communications

Email: ldavidson@namsa.comMedanex Media Contact

Hadewych Van Hauwermeiren

CEO

Email: hadewych.vanhauwermeiren@medanex.com

KEYWORD: OHIO NORTH AMERICA UNITED STATES EUROPE BELGIUM LUXEMBOURG

INDUSTRY KEYWORD: OTHER HEALTH RESEARCH SERVICES PROFESSIONAL SERVICES MEDICAL DEVICES CLINICAL TRIALS VETERINARY SURGERY BIOTECHNOLOGY CONSULTING OTHER HEALTH SCIENCE

SOURCE: NAMSA

Copyright BusinessWire 2022.

PUBLICATION: 03/30/2022 08:30 / DISK: 03/30/2022 08:32

http://www.businesswire.com/news/home/20220330005109/en

Copyright BusinessWire 2022.